Claims for Patent: 4,717,720

Summary for Patent: 4,717,720

Title:	Benzonaphthalene derivatives and compositions
Abstract:	A benzonaphthalene compound has the formula ##STR1## wherein R1 represents (i) ##STR2## or (ii) --CH2 OH; R6 represents ##STR3## or OR7 wherein R7 represents hydrogen, alkyl having 1-20 carbon atoms, monohydroxyalkyl or polyhydroxyalkyl, r' or r" represent hydrogen, lower alkyl, mono or polyhydroxyalkyl, aryl or a residue of an amino acid or a sugar, or together form a heterocycle; R2 represents hydrogen, alkyl having 1-15 carbon atoms, alkoxy having 1-4 carbon atoms or a cycloaliphatic radical; R3 represents hydrogen, hydroxy, alkyl having 1-4 carbon atoms, alkoxy having 1-10 carbon atoms, a cycloaliphatic radical, a thiocycloaliphatic radical or --O--Si(CH3)2 --R8 wherein R8 represents lower alkyl; and R4 and R5 represent hydrogen, lower alkyl, hydroxy or lower acyloxy.This compound is useful in the topical and systemic treatment of dermatologic diseases and in the treatment of the degeneration of conjuctive tissues. The compound also possesses anti-tumor activity.
Inventor(s):	Braham Shroot, Jacques Eustache, Jean-Michel Bernardon
Assignee:	Galderma Research and Development SNC
Application Number:	US06/850,145
Patent Claims:	1. A benzonaphthalene compound of the formula ##STR11## wherein R1 represents (i) ##STR12## R6 represents OR7 wherein R7 represents hydrogen, alkyl having 1-20 carbon atoms, monohydroxyalkyl or polyhydroxyalkyl, R2 represents hydrogen, branched or straight chain alkyl 1-15 carbon atoms, alkoxy having 1-4 carbon atoms or a cycloaliphatic radical, R3 represents hydrogen, hydroxy, branched or straight chain alkyl having 1-4 carbon atoms, alkoxy having 1-10 carbon atoms, a cycloaliphatic radical optionally substituted, a thiocycloaliphatic radical, or --O--Si(CH3)2 --R8 wherein R8 represents linear or branched lower alkyl, provided that at least one of R2 and R3 is adamantyl or adamantylthio and R4 and R5 each independently represent hydrogen, lower alkyl, hydroxy or lower acyloxy,or a salt thereof. 2. A compound of claim 1 wherein said alkyl is selected from the group consisting of methyl, ethyl, isopropyl, butyl and tert.butyl. 3. The compound of claim 1 wherein said alkoxy has 1-10 carbon atoms. 4. The compound of claim 3 wherein said alkoxy is selected from the group consisting of methoxy, ethoxy, isopropoxy, hexyloxy and decyloxy. 5. The compound of claim 1 wherein said lower acyloxy has 1-4 carbon atoms. 6. The compound of claim 5 wherein said lower acyloxy is selected from the group consisting of acetyloxy and propionyloxy. 7. The compound of claim 1 wherein said lower monohydroxyalkyl has 2 or 3 carbon atoms. 8. The compound of claim 7 wherein said lower monohydroxyalkyl is selected from the group consisting of 2-hydroxy ethyl and 2-hydroxy propyl. 9. The compound of claim 1 wherein said polyhydroxyalkyl has 3-6 carbon atoms and 2-5 hydroxy groups. 10. The compound of claim 9 wherein said polyhydroxyalkyl is selected from the group consisting of 2,3-dihydroxy propyl, 1,3-dihydroxy propyl or a residue of pentaerythritol. 11. The compound of claim 1 wherein said cycloaliphatic radical is selected from the group consisting of 1-methyl cyclohexyl and 1-adamantyl. 12. The compound of claim 1 wherein said thiocycloaliphatic radical is 1-adamantylthio. 13. The compound of claim 1 having the formula ##STR13## wherein R'6 represents --OR'7,R'7 represents hydrogen or lower alkyl, R'2 represents hydrogen, alkyl, alkoxy or 1-adamantyl, and R'3 represents hydrogen, hydroxy, alkyl, alkoxy or 1-adamantylthio. 14. The compound of claim 1 selected from the group consisting of6-[p-(1-adamantylthio)phenyl]-2-naphthoic acid; the methyl ester of 6-[p-(1-adamantylthio)phenyl]-2-naphthoic acid, 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid, the methyl ester of 6-[3-(1-adamantyl)-4-methoxyphenyl]2-naphthoic acid. the methyl ester of 6-[3-(1-adamantyl)-4-tert.butyldimethylsilyloxyphenyl]-2-naphthoic acid, the methyl ester of 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthoic acid, 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthoic acid, the methyl ester of 6-[3-(1-adamantyl)-4-decyloxyphenyl]-2-naphthoic acid, 6-[3-(1-adamantyl)-4-decyloxyphenyl]-2-naphthoic acid, the methyl ester of 6-[3-(1-adamantyl)-4-hexyloxyphenyl]-2-naphthoic acid, 6-[3-(1-adamantyl)-4-hexyloxyphenyl]-2-naphthoic acid, the methyl ester of 6-[3-(1-adamantyl)-4-methoxyphenyl]-4-acetoxy-1-methyl-2-naphthoic acid, 6-[3-(1-adamantyl)-4-methoxyphenyl]-4-hydroxy-1-methyl-2-naphthoic acid, the methyl ester of 6-[3-(1-adamantyl)-4-methoxyphenyl]-4-hydroxy-1-methyl-2-naphthoic acid, the methyl ester of 6-[3-(1-adamantyl)-4-methoxyphenyl]-1-methyl-2-naphthoic acid, 6-[3-(1-adamantyl)-4-methoxyphenyl]-1-methyl-2-naphthoic acid. 15. A pharmaceutical composition comprising a pharmaceutically acceptable vehicle suitable for enteral, parenteral, topical or ocular administration and an effective amount of as the active principle at least one compound of claim 1 or a salt thereof. 16. The pharmaceutical composition composition of claim 15 wherein said active principle is present in an amount ranging from 0.0005 to about 5 weight percent based on the total weight of said composition.